Nov 15, 2017 7:35am EST Matinas BioPharma Reports 2017 Third Quarter Financial Results and Provides Corporate Update
Oct 11, 2017 8:05am EDT Matinas BioPharma to Present at the Dawson James Securities 3rd Annual Small Cap Growth Conference
Sep 19, 2017 9:20am EDT Matinas BioPharma to Present at the Cantor Fitzgerald Global Healthcare Conference
Sep 12, 2017 7:30am EDT Matinas BioPharma Retains JSB Partners to Pursue Strategic Options for MAT9001
Aug 08, 2017 6:05am EDT Matinas BioPharma Reports 2017 Second Quarter Financial Results and Reaffirms Clinical and Regulatory Strategy to Advance MAT2203 and MAT2501
Aug 03, 2017 8:05am EDT Matinas BioPharma to Present at the Canaccord Genuity 37th Annual Growth Conference
Jun 26, 2017 6:05am EDT Matinas BioPharma Reports Topline Data from Phase 2 Clinical Study of Orally-Administered MAT2203 for the Treatment of Vulvovaginal Candidiasis
Jun 03, 2017 4:00pm EDT Matinas BioPharma Announces Interim Data from NIH-Conducted Phase 2a Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous Candidiasis
Jun 02, 2017 4:01pm EDT Matinas BioPharma Presents Positive Preclinical Efficacy Data of MAT2203 in Mouse Model of Cryptococcal Meningoencephalitis
